ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort COVID-19 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance

NACompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

June 15, 2023

Study Completion Date

September 15, 2023

Conditions
COVID-19Children With Medical Complexity (CMC)
Interventions
DIAGNOSTIC_TEST

BinaxNOW Rapid Antigen System

"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."

Trial Locations (1)

53792-4108

University of Wisconsin School of Medicine and Public Health, Madison

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Wisconsin, Madison

OTHER